healthcare
-
Dysautonomia conference centers biomarkers and post-exertional malaise
The 14th annual Dysautonomia International conference outside Houston included presentations on the role of autoimmunity in dysautonomia and a biobank initiative for POTS research.
-
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind.
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.
-
Will the new COVID-19 antiviral be accessible?
In June, the Food and Drug Administration approved the drug Xocova (ensitrelvir) as the very first post-exposure prophylaxis for Sars-CoV-2, and if taken within 72 hours, it could stop a SARS-CoV-2 infection in its tracks. The drug is also being studied as a potential Long COVID treatment and even maybe as a preventative. But how…
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
-
Work until you disappear: Long COVID ensnared me in an exploitative health system
The disease emphasizes the racism and ableism of the public health sector in Germany. People with disabilities and chronic illnesses must be prioritized over profits.
-
We must free Long COVID and the people living with it from the mind-body trap
There is a recurring pattern in the history of medicine that still pops up from time to time. When our understanding of a disease lags far behind the need for explanations, biology becomes a matter of one’s own perception. This inevitably shifts the burden of proof back onto the people we should be helping; those…
-
A test for Long COVID can’t leave anyone behind
A test for Long COVID will be transformative, and we should start preparing for its arrival now.
-
A “muddy intervention”: The complex reality of taVNS therapy for Long COVID
People are experimenting with transauricular vagus nerve stimulation (taVNS), with mixed results, ahead of medical guidelines
-
California clinicians gather for Long COVID forum. Recent guides offer direction.
Clinicians and people with Long COVID gathered in Santa Barbara, California, in late March for a forum on advancing clinical care in infection-associated chronic conditions.
-
“It felt like a life-or-death choice”: Pregnancy with Long COVID has many unknowns
Little is known so far about how people with Long COVID experience pregnancy, but some insights can be gleaned from myalgic encephalomyelitis (ME) as well as several ongoing studies in this area.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance